A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Detection of Tn-antigen in breast and prostate cancer models by VVL-labeled red dye-doped nanoparticles




TekijätVerhassel, Alejandra; Kimani, Martha; Gidwani, Kamlesh; Sandholm, Jouko; Gawlitza, Kornelia; Rurack, Knut; Härkönen, Pirkko

KustantajaTaylor and Francis Ltd.

Julkaisuvuosi2024

JournalNanomedicine

Tietokannassa oleva lehden nimiNanomedicine

Vuosikerta19

Numero29

Aloitussivu2463

Lopetussivu2478

ISSN1743-5889

eISSN1748-6963

DOIhttps://doi.org/10.1080/17435889.2024.2405454

Verkko-osoitehttps://doi.org/10.1080/17435889.2024.2405454

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/458628849


Tiivistelmä

Aim: Fluorescence detection of breast and prostate cancer cells expressing Tn-antigen, a tumor marker, with Vicia villosa lectin (VVL)-labeled nanoparticles.

Materials & methods: Breast and prostate cancer cells engineered to express high levels of Tn-antigen and non-engineered controls were incubated with VVL-labeled or unlabeled red dye-doped silica-coated polystyrene nanoparticles. The binding to cells was studied with flow cytometry, confocal microscopy, and electron microscopy.

Results: Flow cytometry showed that the binding of VVL-labeled nanoparticles was significantly higher to Tn-antigen-expressing cancer cells than controls. Confocal microscopy demonstrated that particles bound to the cell surface. According to the correlative light and electron microscopy the particles bound mostly as aggregates.

Conclusion: VVL-labeled nanoparticles could provide a new tool for the detection of Tn-antigen-expressing breast and prostate cancer cells.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Julkaisussa olevat rahoitustiedot
The study was funded as part of the European Network ‘GlycoImaging’ by the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Action grant agreement No. 721297. Working grants were received from the University of Turku Graduate School (Drug Research Doctoral Programme), Ida Montinin Säätiö (The Ida Montin Foundation), K. Albin Johansson Foundation, Paulo Foundation and Lounais-Suomen Syöpäyhdistys (The Cancer Society of Southwestern Finland).


Last updated on 2025-27-01 at 19:25